Citius Pharmaceuticals Inc. (NASDAQ:CTXR) saw a downside of 0.00% to close Monday at $2.04 after subtracting $0.0 on the day. The 5-day average trading volume is 1,502,340 shares of the company’s common stock. It has gained $2.11 in the past week. An average of 2,006,135 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,694,282.
CTXR’s 1-month performance is -1.92% or -$0.04 on its low of $1.94 reached on 09/20/21. The company’s shares have touched a 52-week low of $0.87 and high of $4.56, with the stock’s rally to the 52-week high happening on 06/22/21. YTD, CTXR has achieved 100.00% or $1.02. However, the current price is down -55.26%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Citius Pharmaceuticals Inc. (CTXR) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.24 for the sector.CTXR stock has a beta of 1.53. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.04.
Citius Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 32.50, with the current ratio over the same period at 32.50 meaning that CTXR stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $16000.0 against revenue of $17.71 million.
For the quarterly period ending June 29 this year, Citius Pharmaceuticals Inc.’s cash and short-term investments amounted to $40000.0 against total debt of $1.06 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected CTXR to announce -$0.06 per share in earnings in its latest quarter, but it posted -$0.06, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$5.94 million. CTXR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 9.31 million, with total debt at $1.06 million. Shareholders hold equity totaling $145.98 million
Let’s look briefly at Citius Pharmaceuticals Inc. (CTXR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 48.80% to suggest the stock is trending Neutral, with historical volatility in this time period at 45.44%.
The stock’s 5-day moving average is $2.05, reflecting a +4.62% or $0.09 change from its current price. CTXR is currently trading -2.39% above its 20-day SMA, -6.85% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +7.94% and +85.45% respectively.
Stochastic %K and %D was 44.51% and 44.48% and the average true range (ATR) pointed at 0.09. The RSI (14) points at 49.16%, while the 14-day stochastic is at 36.00% with the period’s ATR at 0.10. The stock’s 9-day MACD Oscillator is pointing at 0.03 and 0.00 on the 14-day charts.
Analysts offering their rating for CTXR stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CTXR as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is CTXR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $10.00 and a high of $10.00, with their median price target at $10.00. Looking at these predictions, the average price target given by analysts is for Citius Pharmaceuticals Inc. (CTXR) stock is $10.00.